Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Lower-risk myelodysplastic syndromes, drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No approved treatment for thrombocytopenia or neutropenia in lower-risk disease.
Whether early disease-modifying treatment changes the natural history rather than the transfusion count.
Iron overload management and quality of life are under-studied.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
More patients achieved transfusion independence with a haemoglobin rise on luspatercept than on epoetin alfa; first-line approval in August 2023.
Imetelstat produced eight-week transfusion independence in significantly more patients than placebo; approved in June 2024.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.